Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

摘要

Following publication of the original article [1], an error was identified in the Cost-per-responder sub-section. The updated conclusion is given below and the changes have been highlighted in bold typeface. The results showed that the adjusted mean total costper-responder was lower for patients receiving aboBoNTA compared to patients receiving onaBoNT-A (€986 vs. €1524), based on the primary treatment response definition.